![LEO Pharma Inc. Announces U.S. Food and Drug Administration (FDA) Expanded Regulatory Approvals for Enstilar® Foam and Taclonex® Topical Suspension in Treatment of Plaque Psoriasis | Business Wire LEO Pharma Inc. Announces U.S. Food and Drug Administration (FDA) Expanded Regulatory Approvals for Enstilar® Foam and Taclonex® Topical Suspension in Treatment of Plaque Psoriasis | Business Wire](https://mms.businesswire.com/media/20190731005636/en/662919/23/leopharma.jpg)
LEO Pharma Inc. Announces U.S. Food and Drug Administration (FDA) Expanded Regulatory Approvals for Enstilar® Foam and Taclonex® Topical Suspension in Treatment of Plaque Psoriasis | Business Wire
![Enstilar (calcipatriene and betamethasone dipropionate) Foam 0.0005%/0.064%, 60 g Leo Pharma (RX) Ingredients and Reviews Enstilar (calcipatriene and betamethasone dipropionate) Foam 0.0005%/0.064%, 60 g Leo Pharma (RX) Ingredients and Reviews](https://cdn1.skinsafeproducts.com/photo/B6338D035CC32D/large_1619041065.png?1619041065)
Enstilar (calcipatriene and betamethasone dipropionate) Foam 0.0005%/0.064%, 60 g Leo Pharma (RX) Ingredients and Reviews
![These highlights do not include all the information needed to use ENSTILAR Foam safely and effectively. See full prescribing information for ENSTILAR Foam. ENSTILAR® (calcipotriene and betamethasone dipropionate) foam, for topical use These highlights do not include all the information needed to use ENSTILAR Foam safely and effectively. See full prescribing information for ENSTILAR Foam. ENSTILAR® (calcipotriene and betamethasone dipropionate) foam, for topical use](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=enstilar-03.jpg&id=641339)